To date, studies returning AD biomarkers have focused on amyloid PET. These studies demonstrate that disclosing such information can be done effectively and safely. There is, however, a notable absence of research on disclosure of tau PET. While the process for returning results will be similar for the two biomarkers, there are important distinctions in what these biomarkers mean and how they should be communicated. This study used a modified Delphi method to develop consensus recommendations on communicating tau PET results to patients and research participants.
Collaboration: This study was led by Dr. Claire Erickson during her time as a post-doctoral researcher in P3MB, under the supervision of Dr. Jason Karlawish and Dr. Emily Largent.
Publications:
Erickson C, O’Brien KS, Largent EA, Harkins K, Coykendall C, Kleid M, Clapp JT, Karlawish J. Expert consensus on communicating tau PET results to persons living with MCI or dementia: Findings from a modified Delphi study. Alzheimers Dement. 2026 Apr;22(4):e71321. doi: 10.1002/alz.71321. PMID: 41950013; PMCID: PMC13060757.